

# Asbestos Exposure and Malignant Pleural Mesothelioma: A Systematic Review of Literature

Cátia Santos<sup>a</sup> Maria dos Anjos Dixe<sup>b</sup> Ema Sacadura-Leite<sup>c</sup> Philippe Astoul<sup>d</sup>  
António Sousa-Uva<sup>e</sup>

<sup>a</sup>NOVA National School of Public Health, Universidade NOVA de Lisboa, Center for Innovative Care and Health Technology (ciTechCare), Polytechnic of Leiria, Leiria, Portugal; <sup>b</sup>Center for Innovative Care and Health Technology (ciTechCare), Polytechnic of Leiria, Leiria, Portugal; <sup>c</sup>Department of Occupational and Environmental Health, NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Comprehensive Health Research Center (CHRC), Lisbon, Portugal; <sup>d</sup>Department of Thoracic Oncology, Pleural Diseases, and Interventional Pulmonology, North Hospital, Aix-Marseille University, Marseille, France; <sup>e</sup>NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal

## Keywords

Asbestos · Exposure · Malignant pleural mesothelioma · Mortality

## Abstract

**Background:** The relationship between exposure to asbestos and malignant pleural mesothelioma (MPM) is already well established. Nevertheless, much remains to be known about exposure thereto and the incidence and mortality from MPM. **Objective:** This systematic review aims to map the relationship between asbestos and MPM by studying the exposure to asbestos and the incidence and mortality of MPM. **Methods:** A systematic review was conducted relating asbestos and MPM. Exposure to asbestos, incidence, and mortality by MPM was reviewed. PubMed, Web of Science, Cochrane Library, RCAAP, DART-Europe, and the reference lists of included studies were searched, from January 1, 1960, to December 31, 2020. Methodological quality was checked, the risk of bias analysis was performed, a level of evidence grade was assigned, and descriptive data analysis was per-

formed. **Results:** 3,484 unique citations were identified, which included seventeen observational studies that met inclusion criteria with a total of 1,104 patients. Heterogeneity is present between the included studies which range from a case series of 16 retrospective studies and 1 prospective study. Studies were mostly conducted in Europe, particularly in Italy (6), and were published between 1969 and 2020. The mean age of patients is approximately 66 years with a latency period between the first exposure and diagnosis of approximately 42 years. 14 studies present data regarding the occupational context and chrysotile and crocidolite are the most studied types of fibre. The incidence of cases occurred between the interval 1966 and 2014 and in 9 studies the mortality rate was 100% of patients. **Conclusion:** There is high evidence to support the relationships between asbestos and MPM. However, the relatively scant information provided by the studies reinforces the need for well-conducted research and implementation of National Mesothelioma Surveillance Centres at a global level.

© 2023 The Author(s). Published by S. Karger AG, Basel on behalf of NOVA National School of Public Health

## Exposição Ao Amianto E Mesotelioma Maligno Da Pleura: Uma Revisão Sistemática Da Literatura

### Palavras Chave

Amianto · Exposição · Mesotelioma maligno da pleura · Mortalidade

### RESUMO

**Introdução:** A relação entre a exposição ao amianto e o mesotelioma maligno da pleura (MMP) já está bem estabelecida. No entanto, ainda muito há a saber sobre a exposição ao mesmo e a incidência e mortalidade do MMP.

**Objetivo:** Esta revisão sistemática visa mapear a relação entre o amianto e o MMP, estudando a exposição ao amianto e a incidência e mortalidade do MMP. **Métodos:** Foi realizada uma revisão sistemática relacionada com o amianto e o MMP. A exposição ao amianto, incidência, e mortalidade por MMP foram revistas. PubMed, Web of Science, Cochrane Library, RCAAP, DART-Europe e as listas de referência dos estudos incluídos foram pesquisados, de 1 de janeiro de 1960 a 31 de dezembro de 2020. A qualidade metodológica foi verificada, bem como o risco de análise de enviesamento, e foi realizada uma análise descritiva dos dados. **Resultados:** Foram identificadas 3,484 citações únicas, que incluíam 17 estudos observacionais, que preenchem os critérios de inclusão com um total de 1,104 pacientes. A heterogeneidade está presente entre os estudos incluídos, que variam entre uma série de 16 estudos retrospectivos e 1 estudo prospetivo. Os estudos foram realizados principalmente na Europa, particularmente em Itália (6), e foram publicados entre 1969–2020. A idade média dos pacientes, é de aproximadamente 66 anos, com um período de latência entre a primeira exposição e o diagnóstico de aproximadamente 42 anos. 14 estudos apresentam dados relativos ao contexto ocupacional e o crisótilo e a crocidolite são os tipos de fibra mais estudados. A incidência de casos ocorreu entre o intervalo 1966–2014 e em 9 estudos a taxa de mortalidade foi de 100% dos pacientes. **Conclusão:** A evidência demonstra a relação entre o amianto e MMP. No entanto, a informação relativamente escassa fornecida pelos estudos, reforça a necessidade de investigação dirigida e mais aprofundada e implementação de Centros Nacionais de Vigilância do Mesotelioma a nível mundial.


© 2023 The Author(s). Published by S. Karger AG, Basel on behalf of NOVA National School of Public Health

### Introduction

Widely used since ancient times for its important chemical and physical characteristics [1, 2], asbestos is recognized in all its varieties as a human carcinogen by the International Agency for Research on Cancer (IARC) [3] and as the leading cause of cancer-associated occupational exposure in industrialized countries [3–5]. Since 2004, the World Health Organization (WHO) estimates that approximately 125 million individuals were exposed to asbestos at their workplace and that 107,000 deaths and 1,523,000 disability-adjusted life years occurred each year as a result of diseases related to their exposure [6, 7]. Asbestos can cause diseases such as lung, laryngeal, ovarian, and gastrointestinal cancer, asbestosis, and mesothelioma [8–10], but it is malignant pleural mesothelioma (MPM), of monofactorial origin, that has been assumed to be the determining factor in the study of this subject [5, 8, 11, 12]. Although the relationship between asbestos exposure and MPM is well known [13], the most studied occupational agent since 1965 with more than 12,000 bibliographic references on MEDLINE, many of the published studies is related to litigation against asbestos manufacturers, suppliers, and providers of asbestos-containing products [14] leading to the fact that much is still unknown about asbestos consumption and its location, as well as about incidence and mortality from MPM.

Increased incidence and mortality rates from MPM reflect the massive use of asbestos in industrialized countries in the past but also the current production and consumption in many developing countries [13, 15]. Despite all the efforts to ban its use, to date, only 67 countries have banned its use [16]. In the USA, it remains legal with an estimated consumption, between 2016 and 2020, of 535 tonnes [17]. In 2016, India and China were the world's leading asbestos consumers (308.000/288.000 tonnes, respectively) and, in 2018, Russia represented the largest producer of asbestos used worldwide (710.000 tonnes) [16]. For this reason, it is also estimated that diseases related to this exposure, notably MPM, will continue to be a major health problem for many decades to come, increasing 5–10% per year, in industrialized countries, in a heterogeneous manner [8, 15, 18].

In order to define directives to raise awareness and to allow a public institution to plan and aim for its elimination, as a response to the joint work of the International Labour Organization (ILO) with the World Health Organization (WHO), which led to the Parma Declaration in 2010 [19], many countries have already set up ongoing epidemiological surveillance projects of both mortality



**Fig. 1.** PRISMA flow diagram.

and incidence of this disease [20] (National Mesothelioma registries in Australia, France, South Korea, and Italy [21] and mesothelioma mortality in UK [22], US [23], Spain [24], Greece [25], Brazil [26], and Italy [27]). This systematic review aims to map the relationships between asbestos and MPM by studying the exposure to asbestos and the incidence and mortality of MPM. By mapping these aspects, we can contribute to bringing to the fore the actuality of this problem and consequently to the need to broaden the focus of research and implementation of National Mesothelioma Surveillance Centres at a global level.

## Methods

This systematic review was reported following the PRISMA 2020 guideline for reporting systematic reviews [28].

### *Protocol and Registration*

A protocol was developed using the guidelines of the Joanna Briggs Institute (JBI) approach to evidence-based healthcare – systematic reviews of aetiology and risk [29] – and it was registered in the Prospero database (CRD:42021242963, [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42021242963](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021242963)), prior to conducting the search.

### *Eligibility Criteria*

This review includes all studies that address the relationship between asbestos and MPM in terms of exposure to asbestos, incidence, and mortality by MPM. Studies presenting data on other types of mesotheliomas were also accepted, provided it was possible to exclude data relating to MPM. We restricted our search to studies written in English, French, and Portuguese.

All studies that focus on humans diagnosed with MPM by exposure to asbestos, regardless of age and gender, were included. All studies in occupational and non-occupational contexts were also included. The relationship between exposure to asbestos and MPM was analysed in an occupational and non-occupational context because, although occupational exposure is the most frequent

[13, 15], this relationship has also been demonstrated in non-occupational exposure, namely, in women [30, 31]. Only studies in which exposure was confirmed and that only pertained to asbestos, regardless of dose and exposure time, were included.

#### *Search Strategy*

Systematic searches were conducted from September 11 to 15, 2021. We searched for eligible published and unpublished studies in databases and sources of grey literature. The databases included were PubMed (using the terms MESH), the Web of Science, and the Cochrane Library, as well as the sources of grey literature, i.e., the Open Access Scientific Repositories of Portugal, DART-Europe E-theses Portal, from January 1, 1960, to December 31, 2020. We extended our research to 1960 since that was the year in which the first study demonstrating a causal relationship between asbestos exposure and MPM was published [1, 2, 14, 32] and also marked the period of increased incidence of and mortality from malignant mesothelioma [33].

#### *Study Selection*

Databases searches were saved, and duplicated records were identified and removed. Two independent reviewers (CS, MAD), from a group of five (CS, MAD, ESL, PA, and ASU), screened titles and abstracts. A third reviewer helps to resolve disagreements (ASU). After potentially eligible studies had been selected, two independent researchers reviewed the retrieved full-text studies for eligibility; one researcher (CS) screened all studies; and four researchers (MAD, ESL, PA, and ASU) collectively screened the same studies for agreement; a third reviewer (ASU) read studies to resolve disagreements. The reference lists of identified studies were reviewed for additional relevant studies. Several study authors were contacted to assess to the full-text article.

After the studies were screened, there was further application of the critical appraisal checklist for cohort studies (online suppl. Appendix 1; see [www.karger.com/doi/10.1159/000527971](http://www.karger.com/doi/10.1159/000527971) for all online suppl. material), case-control studies (online suppl. Appendix 2), and analytical cross-sectional studies (online suppl. Appendix 3) [29]. A PRISMA flow diagram of included studies was performed. A list of excluded studies and reasons for exclusion was also performed and generally presented in the PRISMA flow diagram (Fig. 1).

#### *Data Collection Process*

Both reviewers independently extracted study data into a prepared spreadsheet (Excel®, Microsoft Corporation, Redmond, WA). The data consisted of the last name of the first author, publication date, country of origin, language, primary aim, method, sample size, gender, age, period/time of study, country in study, data source, exposition characteristics (type, history, exposure time, age at first exposure, via, latency, fibre type, fibre dimensions, cumulative exposure), incidence (age at incidence, diagnosis year), and mortality (number of deaths).

Two reviewers independently extracted data from each article using the constructed form. To ensure consistent data extraction by all reviewers, we pilot the form in five studies. During the pilot, reviewers clarified differences in interpretation and the standardized data extraction. After the pilot, studies used are randomly assigned and screened again during the data extraction. One researcher (CS) extracted data from all studies, and five researchers (MAD, ESL, PS, and ASU) collectively extracted data from the

same studies. Any disagreements in data extraction were settled by consensus among each pair of reviewers. The information entered on the form was subsequently analysed.

#### *Risk of Bias (Quality) Assessment*

To minimize the risk of bias and increase the quality of this review, only studies related to MPM, the only disease known to date to be monofactorial after exposure to asbestos [5, 8, 11, 12], were included. Data were always reviewed by two reviewers, and a third reviewer read studies to resolve disagreements. To assess the quality and strengthening of the studies [34], the STROBE checklist was applied (STROBE checklist: cohort, case-control, and cross-sectional studies).

#### *Data Analysis*

The identified studies' heterogeneity in design and reported outcomes precluded a meta-analysis. Results from individual studies are reported descriptively and are qualitatively summarized.

## **Results**

#### *Study Selection*

The databases search yielded 4,121 hits (PubMed [ $n = 1,356$ ], Web of Science [ $n = 2,710$ ], and the Cochrane Library [ $n = 55$ ]) and the registers search yielded 23 hits (Open Access Scientific Repositories of Portugal [ $n = 10$ ] and DART-Europe E-theses Portal [ $n = 13$ ]) (Fig. 1). Assessment of selected studies' reference lists identified no additional eligible studies. A total of 3,484 unique papers were identified and screened by title and abstract; 3,425 papers were excluded for not presenting inclusion criteria. Fifty-nine papers were read to determine eligibility for inclusion. Seventeen met the inclusion criteria and were included in the review (Table 1), while 42 papers were excluded (32 for not presenting inclusion criteria, 8 for unclear criteria, 1 for duplicate sample, and 1 for lack of quality) (Fig. 1).

#### *Study Characteristics*

Of the seventeen studies identified, sixteen were retrospective and one was prospective. They were all observational studies (twelve analytical cross-sectional, three retrospective cohort, and two retrospective case-control). All were published in English, between 1969 and 2020, Italy being the country of origin of most studies. The identified studies included 1,104 participants. Eleven of the studies were conducted in Europe, one in South Africa, one in the USA, one in Mexico, one in Australia, and two were conducted jointly between Australia/UK and Australia/Italy. Studies were conducted in occupational and non-occupational contexts. In five studies, the data presented refer to hospital data only, ten studies to data

**Table 1.** Characteristics of the included studies [35–51]

| First author/date/study country                  | Language | Primary aim   | Method                                      | Sample size, N* | Country            | Data source           | Period/study time, range/mean years |
|--|----------|---|---|-----------------|--------------------|-----------------------|-------------------------------------|
| Bianchi et al. (2011) [35], Italy                | English  | To investigate the reasons why is so rare MM developed at very old ages   | Retrospective-observational cross-sectional | 8               | Italy              | Hospital              | 1968–2008/40y                       |
| Edge et al. (1978) [36], UK                      | English  | To describe MPM patients diagnosed in Barrow-in-Furness in relation to incidence and occupation   | Retrospective-observational cross-sectional | 49              | UK                 | Hospital              | 1966–1976/10y                       |
| Acheson et al. (1981) [37], UK                   | English  | To describe MPM cases identified in a factory using amosite and chrysotile asbestos   | Retrospective-observational cohort          | 4               | UK                 | Databases             | 1945–1980/35y                       |
| Cochrane and Webster I (1978) [38], South Africa | English  | To prove that a history of exposure to asbestos can be established in a significant number of cases<br>Influence the recognition of mesothelioma as an occupational disease   | Retrospective-observational cross-sectional | 69              | South Africa       | Databases             | 25y                                 |
| Schneider et al. (1996) [39], Germany            | English  | To overview of asbestos-induced pleural mesotheliomas that are linked to indoor inhalation by household contacts  | Retrospective-observational cross-sectional | 6               | Germany            | Hospital              | 1986–1994/8y                        |
| Vianna and Polan AK (1978) [40], USA             | English  | To assess the possibility that household exposure might be a major risk factor for females with MM  | Retrospective-observational case-control    | 11              | US                 | Databases             | 1967–1977/10y                       |
| Méndez-Vargas et al. (2010) [41], Mexico         | English  | To identify the characteristics of pleural mesothelioma in patients exposed to asbestos   | Retrospective-observational cross-sectional | 21              | Mexico             | Hospital              | 2000–2004/4y                        |
| Merler et al. (2003) [42], Italy                 | English  | To report the occurrence of mesotheliomas in Italy among subjects who worked, when migrant, at a cement-asbestos factory in Niederurmen, Switzerland, and had resettled to the home country   | Retrospective-observational cross-sectional | 13              | Italy              | Databases             | 1984–2000/16y                       |
| Orriols et al. (2020) [43], Spain                | English  | To describe clinical and epidemiological characteristics of patients diagnosed with malignant asbestos-related disease  | Prospective-observational cross-sectional   | 105             | Spain              | Hospital              | 2007–2016/9y                        |
| Swiatkowska et al. (2017) [44], Poland           | English  | To determine the importance of temporal patterns, especially the time since the end of exposure in the risk of pleural mesothelioma among the workers who were exposed to asbestos dust in the past   | Retrospective-observational case-control    | 131             | Poland             | Databases             | 2000–2014/14y                       |
| D'Agostin et al. (2017) [45], Italy              | English  | To examine the available residential and familial history and occupational and clinical data of individuals diagnosed with MM, attributable only to asbestos brought by another family member, from the Friuli Venezia Giulia Mesothelioma Register | Retrospective-observational cross-sectional | 35              | Italy              | Databases             | 1995–2014/19y                       |
| Finn et al. (2012) [46], Australia/UK            | English  | To review the post-mortem findings in mesothelioma patients from two regional centres in Western Australia and England  | Retrospective-observational cross-sectional | 318             | Australia<br>UK    | Databases             | 1969–2009/40y***<br>2005–2008/3y    |
| Berry et al. (2012) [47], Australia              | English  | To report the number of pleural and peritoneal mesotheliomas that have occurred in former Wittenoom crocidolite workers to the end of 2008, to compare this with earlier predictions, and to relate the mesothelioma rate to amount of exposure     | Retrospective-observational cohort          | 281             | Australia<br>Italy | Databases<br>Hospital | 1960–2008/48y                       |



**Table 1** (continued)

| First author/date/study country         | Language | Primary aim  | Method                                      | Sample size, N* | Country   | Data source            | Period/study time, range/mean years |
|---|----------|--|---|-----------------|-----------|------------------------|-------------------------------------|
| Mirabelli et al. (2008) [48], Italy     | English  | To report on a survey of data in the RMM, conducted to identify cases aetiologically related to the mine, including cases among non-occupationally exposed individuals | Retrospective-observational cohort          | 25              | Italy     | Databases              | 1980–2007/27y                       |
| Karjalainen et al. (1994) [49], Finland | English  | To describe 4 cases of mesothelioma that occurred in the ongoing follow-up of the cohort of Finnish anthophyllite miners and millers                                   | Retrospective-observational cross-sectional | 3               | Finland   | Databases<br>Companies | 1936–1991/55y**                     |
| Dodoli et al. (1992) [50], Italy        | English  | To describe a cluster of cases of pleural mesothelioma attributable to non-occupational exposure to asbestos in the towns of La Spezia and Leghorn                     | Retrospective-observational cross-sectional | 16              | Italy     | Databases              | 1975–1988/13y<br>1958–1988/30y***   |
| Milne and Sc B (1969) [51], Australia   | English  | To describe 15 cases of MPM occurring in Victoria  | Retrospective-observational cross-sectional | 9               | Australia | Hospital               | 1962–1968/6y                        |

Hospitals: Trieste and Monfalcone, High Carley and North Lonsdale, Institut und Poliklinik Für Arbeit, Mexico Reference Oncologic Hospital, Swiss Insurance Institute, Parc Tauli Hospital, Sabadell, Major Public Hospitals in Melbourne, Sir Charles Gairdner Hospital. Databases: National Health Service Central Register at Southampton, UK National Cancer Register, South Africa National Research Institute for Occupational Diseases, US Bureau of Vital Records of the State Health Department, Poland Amiantus Programme, Friuli Venezia Giulia Mesothelioma Register, the Western Australia Mesothelioma Registry, Coroner's Office post-mortem reports from the Avon area, Italy Deaths and cancer notifications, National Death Index through the Australian Institute for Health and Welfare (AIHW) and the Western Australian Registrar for General for births, deaths, and marriages, National Cancer Statistics Clearing House through the AIHW, the Australian Mesothelioma Registry, and the Western Australian Cancer Registry (including the Western Australian Mesothelioma Registry), Registry of Malignant Mesotheliomas of Piedmont, Statistics Finland, Finnish Cancer Registry. MM, malignant mesothelioma; MPM, malignant pleural mesothelioma; RMM, Registry of Malignant Mesotheliomas; UK, United Kingdom; USA, United States of America; y, year. \* (N) denotes total number of MPM subjects in study. \*\* Data assumed taking into consideration the data presented in the study. \*\*\* For calculating the average, the longest period was considered.

**Table 2.** STROBE checklist: cohort, case-control, and cross-sectional studies to assess the quality and strengthening of the studies

|                          | Vianna et al | Swiatkowska et al | Bianchi et al | Edge et al | Acheson et al | Cochrane et al | Schneider et al | Méndez-Vargas et al | Merler et al | Orris et al | D'Agostin et al | Finn et al | Berry et al | Mirabelli et al | Jarvholm et al | Karjalainen et al | Dodoli et al | Milne |   |
|--------------------------|--------------|-------------------|---------------|------------|---------------|----------------|-----------------|---------------------|--------------|-------------|-----------------|------------|-------------|-----------------|----------------|-------------------|--------------|-------|---|
| Title and abstract       | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| <i>Introduction</i>      |              |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Background/rationale     | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Objectives               | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| <i>Methods</i>           |              |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Study design             | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Setting                  | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Participants             | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Variables                | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Data sources/measurement | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Bias                     |              |                   |               |            |               |                |                 |                     |              |             | x               |            |             |                 |                |                   |              |       |   |
| Study size               | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Quantitative variables   | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Statistical methods      | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| <i>Results</i>           |              |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Participants             | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Descriptive data         | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Out come data            | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Main results             | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Other analyses           | x            | x                 |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| <i>Discussion</i>        |              |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Key results              | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Limitations              | x            | x                 | x             | x          | x             |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Interpretation           | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| Generalizability         | x            | x                 | x             | x          | x             | x              | x               | x                   | x            | x           | x               | x          | x           | x               | x              | x                 | x            | x     | x |
| <i>Other information</i> |              |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |
| Funding                  | x            |                   |               |            |               |                |                 |                     |              |             |                 |            |             |                 |                |                   |              |       |   |

obtained from national databases only, one to data obtained from national databases and mining company, and one to data obtained in national databases and hospital. The overall studied period was on average 24 years for the retrospective studies and 9 years for the prospective study, with a global range between 1936 and 2016.

#### *Methodological Quality/Risk of Bias*

The result of the appraisal of each study is presented in Table 2. The specific STROBE checklist used includes a number of questions that pertains to combined case-control, cohort, and cross-sectional studies [34]. The studies were all observational. The fact that the research was extended to 1960 means that many studies were not designed according to current quality and strengthening guidelines. Therefore, in general, studies had limited enrolment, two of them did not present the objectives described in the introduction, three did not present study limitations, four explicitly specified the risk of bias, and only six referred to fundings.

#### *Findings of Individual Studies*

Table 1 shows the summarized findings of the included studies' characteristics. Patients' characteristics, asbestos exposure, and incidence and mortality to MPM are described in more detail below and summarized in Table 3.

#### *Characteristics of Participants*

Of the 1,104 patients under study, 855 were male, 180 were female, and 69 were unknown. In only twelve studies (five occupational, five combined occupational and non-occupational, and two para-occupational) was possible to calculate the average age, which was approximately 66 years, with a range between 30 and 93 years. Four studies (one occupational, two combined occupational and non-occupational, and one unknown) did not present data regarding the age of patients and one study (occupational) presented data regarding classes <50 years, 50–79, and 80 years. All cases of MPM included in the study were validated clinically and/or histologically.

#### *Characteristics of Exposure*

Seven studies were related to occupational exposure, two to non-occupational exposure (para-occupational), seven to combined occupational and non-occupational (environmental and para-occupational) exposure, and one was unknown. In all studies, inhalation was via exposure. The average exposure time was 16 years in eight studies (five occupational, two combined occupational

and non-occupational, and one para-occupational), with a range of 3–32 years. One study (occupational) presented a mean time of exposure >20 years and in eight studies (one occupational, five combined occupational and non-occupational, one para-occupational, and one unknown), it was unknown.

In eight studies (five occupational, one combined occupational and non-occupational, and two para-occupational), it was possible to determine the interval period of the first exposure, 1915–1992. The mean age at first exposure was approximately 27 years (obtained in six studies – four occupational and two para-occupational). The mean age at first exposure was 29 years in occupational studies and 22 years in para-occupational studies. The mean age at first exposure could not be obtained in combined occupational and non-occupational studies. The exposure happened between 1915 and 1970 in occupational exposure, 1920–1992 in para-occupational exposure, and 1925–1989 in occupational and non-occupational exposure. The exposure time was higher in the studies carried out in combined occupational and non-occupational studies, namely, 28 years, whereas it was 13 years in occupational studies and 12 in para-occupational.

Only in seven studies (five occupational, one combined occupational and non-occupational, and one unknown context), the type of asbestos fibre to which the patients were exposed is presented, namely, chrysotile, crocidolite, amosite, and anthophyllite. Chrysotile was identified in four studies and crocidolite in three studies. Two studies were conducted in the UK, where chrysotile was the type of asbestos under study, and three in Australia, where the type of asbestos was crocidolite. Only one occupational study had data on mean cumulative exposure index – 44 mg/m<sup>3</sup> – and another occupational study had mean lengths fibres of 3.9–5.1 µm. Of the nine non-occupational studies with data concerning the non-occupational context, eight referred to para-occupational exposure (household) and five to environmental exposure (living near mines and factories producing products containing asbestos). In fourteen studies concerning occupational exposure, shipbuilding, construction, production of asbestos-containing products, and mining were the main occupations of the patients.

#### *Mesothelioma Latency Period*

In twelve studies (five occupational, four combined occupational and non-occupational, two para-occupational, and one unknown), the average latency period was approximately 42 years, with a minimum latency time of 1



**Table 3.** Patient characteristics, asbestos exposure, and incidence and mortality to MPM [35–51]

| First author/date/study country                | Gender, n     | Range/mean age         | Exposition type/history                            | Mean exposure time | Range first exposure/mean age at first exposure | Range/mean latency time | Fibre type                          | Mean lengths fibres, µm | Mean cumulative exposure index, mg/m <sup>3</sup> | Range MPM age incidence/diagnosis year | Number of deaths | Time between diagnosis/death |
|--|---------------|------------------------|--|--------------------|---|-------------------------|-------------------------------------|-------------------------|---|--|------------------|------------------------------|
| Bianchi et al. (2011) [35], Italy              | 7 M<br>1 F    | 90–93/91*y             | Occupational                                       | >20y               | 1915–1941/24*y                                  | 64–75/68*y              |                                     |                         |   | 1987–2009                              | 8/8              |                              |
| Edge et al. (1978) [36], UK                    | 47 M<br>2 F   | 32–74/60y              | Occupational<br>Para-occupational                  |                    |   | 20–62/42y               |                                     |                         |   | 1966–1976                              | 46/49            | 1y                           |
| Acheson et al. (1981) [37], UK                 | 4 M           | 39–78/59*y             | Occupational                                       | 3*y                | 1954–1965/43*y                                  | 11–22/17*y              | Amosite<br>Chrysotile               |                         |   | 1971–1979*                             | 4/4              |                              |
| Cochrane and Webster (1978) [38], South Africa |               |                        | Occupational<br>Environmental                      |                    |   | 9–40                    |                                     |                         |   |  |                  |                              |
| Schneider et al. (1996) [39], Germany          | 1 M<br>5 F    | 42–68/60*y             | Para-occupational                                  | 12*y               | 1950–1969/25*y                                  | 17–38/32*y              |                                     |                         |   | 1985–1992*                             | 6/6              | 1y                           |
| Viana and Polan AK (1978) [40], USA            | 11 F          | 30–85/57*y             | Occupational<br>Para-occupational<br>Environmental |                    |   | 2–23/13*y               |                                     |                         |   | 1968–1975                              | 11/11            |                              |
| Méndez-Vargas et al. (2010) [41], Mexico       | 20 M<br>1 F   | 57*y                   | Occupational<br>Para-occupational<br>Environmental |                    |   | 38*y                    |                                     |                         |   | 56*y                                   | 21/21            | 1y                           |
| Merler et al. (2003) [42], Italy               | 11 M<br>2 F   | 47–68*/55*y            | Occupational                                       | 12*y               | 1953–1970/24*y                                  | 25–38*/30*y             |                                     |                         |   | 1984–2000                              | 13/13            |                              |
| Oriols et al. (2020) [43], Spain               | 70 M<br>35 F  |                        | Occupational<br>Para-occupational<br>Environmental | 23y                |   | 51y                     |                                     |                         |   |  |                  |                              |
| Swiatkowska et al. (2017) [44], Poland         | 95 M<br>36 F  | <50y<br>50–79y<br>≥80y | Occupational                                       | 14y                | 26y   | 1–40/36y                | Chrysotile mixed<br>with chrysotile | 44                      |   |  |                  |                              |
| D'Agostin et al. (2017) [45], Italy            | 2 M<br>33 F   | 50–93/77y              | Para-occupational                                  |                    | 1920–1992/18y                                   | 25–91/59y               |                                     |                         |   | 1996–2014                              | 34/35            | 1y                           |
| Finn et al. (2012) [46], Australia/UK          | 291 M<br>27 F | 68y                    | Occupational                                       |                    |   |                         | Crocidolite (WA)<br>Chrysotile (UK) |                         |   |  | 318/318          |                              |
| Berry et al. (2012) [47], Australia            | 268 M<br>13 F |                        | Occupational                                       |                    | 35y   |                         | Crocidolite                         |                         |   | 1960–65–2006–08                        | 268/281          |                              |
| Mirabelli et al. (2008) [48], Italy            | 17 M<br>8 F   | 36–74*/64*y            | Occupational<br>Para-occupational<br>Environmental | 32*y               | 1925–1989*                                      |                         |                                     |                         |   | 1975–2006                              |                  |                              |
| Karjalainen et al. (1994) [49], Finland        | 3 M           | 57–75/65*y             | Occupational                                       | 21*y               | 1929–1950                                       | 46*y                    | Anthophyllite                       | 3.9–5.1                 |   | 1986–1991*                             | 3/3              |                              |
| Dodoli et al. (1992) [50], Italy               | 13 M<br>3 F   | 60–87/74*y             | Occupational<br>Para-occupational                  |                    |   |                         | Chrysotile                          |                         |   |  | 16/16            |                              |
| Milne and ScB (1969) [51], Australia           | 6 M<br>3 F    |                        | Occupational                                       | 14*y               | 1920–1942                                       |                         | Crocidolite                         |                         |   |  |                  |                              |

Occupational history: administration; asbestos mining; asbestos textile handling; asbestos transport workers; asbestos-cement workers; boiler maker; boiler; building; buffing; carding asbestos fibres; caulker and burner; construction industry; copper smith; cutting; direct production; driller; drivers and loaders; electrical; electrician; engineer; engineer draughtsman; fibrier and bagging fibre on beater floor; finishing; former miners and millers; inspector of boards and 'on the ovens'; joiner; labourer; lagger; locomotive workshops; machine hand; maintaining and setting winding machine; medical officer on asbestos mine; miners; mixing and pipes production; mixing cement and asbestos; moulding and finishing; musician; naval dockyard worker; painter; pipes production; pipes production and cutting; pipes production and finishing; plumber; power station supervisor; production; shipbuilding; shipwright; shipyard employee; shoemaker; special cutter in the light-materials division; surfacing with asbestos tailings; textile worker; welder; winding asbestos string on the welding rod; wine dealer. Non-occupational history: environmental (living near mines and factories producing products containing asbestos); para-occupational (household); E, environmental; F, female; M, male; MPM, malignant pleural mesothelioma; O, occupational; PA, para-occupational; UK, United Kingdom; WA, Western Australia; y, year. \*Data assumed taking into consideration the data presented in the study.

year and a maximum of 91 years. The latency period is 46 years in the para-occupational studies (between 17 and 91 years), 39 years in occupational (between 1 and 75 years), and 36 years in the studies carried out in combined occupational and non-occupational (between 2 and 62 years).

Ten studies (four occupational, three combined occupational and non-occupational, two para-occupational, and one unknown) presented the period of incidence and, in general, the first case was identified in 1966 and the last in 2014. For occupational context, the range of diagnosis was 1984–2000, in combined occupational and non-occupational it was 1966–2006, and in para-occupational it was 1985–2014.

#### *Mesothelioma Incidence by Sex and Age*

From the data that can be extracted from occupational studies and non-occupational studies, it is possible to see that, in occupational studies, men had a higher incidence of MPM, varying between 67 and 100% of the total number of patients included. Nevertheless, in para-occupational studies, women had a higher incidence (>83%). In the combined occupational and non-occupational studies, the incidence rate was also higher in men, with rates between 67 and 100%. In what regards the mean age of the patients of MPM, it can be determined that in occupational studies it was 68 years old, in para-occupational studies 69 years old, and in combined occupational and non-occupational studies it was 62 years old.

#### *Mesothelioma Mortality*

In twelve studies, it was possible to collect data on the number of patients who died by the time of the publication (five occupational, four combined occupational and non-occupational, two para-occupational, and one unknown). The mortality rate was >89%, being in nine of them, 100% (five occupational, three combined occupational and non-occupational, one para-occupational).

Only four studies (two occupational and non-occupational and two para-occupational) presented data regarding the interval between the time of diagnosis and death, which is approximately 1 year. In five studies, the data were obtained post-mortem, and in eight it was unknown. In occupational studies, the mortality rate was 100%, while in para-occupational studies it was 97–100%, and in occupational and non-occupational studies 94–100%.

#### *Risk of Bias across all Studies*

An assessment of bias across all studies was not conducted as the studies could not be compared due to the heterogeneity of outcomes, differences in study design, and risk of bias.

## **Discussion**

### *Summary of Evidence*

In this systematic review, abundant studies were identified, reinforcing the fact that asbestos is the most widely studied occupational agent [14]. All seventeen included studies are observational and heterogeneous among themselves. This can be explained by the fact that to study the association between an exposure risk and a particular disease, epidemiological studies are normally the most widely used [14]. However, when it comes to the relationship between exposure to asbestos and MPM, in which much is still unknown about dose response, cumulative exposure, and exposure history, aggravated by the fact that MPM is a rare disease, difficult to diagnose, and with a long latency period, studies tend to be fraught with error and flawed in terms of bias, making these studies invalid for meta-analysis [14]. Another important factor is that the studied type of exposure must be similar, which was not the case in the studies in general because of mixed contexts such as occupational and non-occupational and, within occupational, with different occupations [14]: this is exactly what we found in the seventeen studies included in our systematic review, which, as may be seen in Table 3, present mixed exposure contexts.

Nevertheless, it is known that Europe is the current centre of the asbestos-related diseases burden [52], in particular Italy, which is known to be among the largest producers and users of asbestos in the 20th century, until its ban in 1992 [20, 53], and the highest incidence reported of mesothelioma in the world, in the Italian Province of Genoa (5.8/100 000) [54], even if the highest malignant mesothelioma incidence in the world occurs in the UK and Australia [55]. These data agree with the data found in this systematic review, in which eleven of the seventeen studies were conducted in Europe, six in Italy, and two in UK. Another three were conducted in Australia [1], Italy and Australia [1], and the UK and Australia [1].

It can be stated that all individuals have been exposed to low doses of asbestos at least once in their lives [14, 56]. A number of studies included in this systematic review support that occupational exposure is the most frequent [57], namely, in men [58], while non-occupational exposure is more frequent among women [13], occurring in domestic settings through cross-contamination with relatives working with asbestos or dwellings containing degraded materials, polluted air from local businesses producing/handling asbestos, the handling of friable materi-

als, contact with places where these minerals form naturally, and in natural disasters [59, 60]. Studies show that there is a risk of mesothelioma from all types of exposure, namely, environmental [5], the type of exposure that remains a major issue [61] because of the difficulty in quantifying it. The data collected in the five studies included reinforce this situation, insofar as exposure related to living near mines and factories manufacturing products containing asbestos means that this exposure is often deemed indirect and subjective, even by the individuals themselves, who usually state that they have never been exposed to asbestos.

Exposure, previously linked, in the post-World War II context, to asbestos mines and the manufacture of products containing asbestos, suffered with the cessation of the production of these products and the closure of the mines in industrialized countries such as the UK, a clear change. In this sense, it has been verified a decrease in risk for those associated with mines and manufacturing and an increased risk for those associated with construction, such as carpenters, plumbers, and other tradespeople [62], and more recently in workers who demolish, repair, or refurbish structures, plants, ships, or products containing asbestos [14]. In the non-occupational context, concern has also been growing as asbestos has been identified in numerous public buildings and schools [14]. Due to the long latency period and to the fact that the directives to ban and manage the use of asbestos are recent, studies included in this systematic review refer to exposures that occurred between 1915 and 1992, which does not allow to reflect and support these data.

All asbestos fibres are carcinogenic and genotoxic [4] and are not possible to define a threshold dose for exposure below which it cannot be stated with certainty that carcinogenic effects are not observed (“threshold”) [63, 64]. Chrysotile, crocidolite, and amosite [65] are the varieties of asbestos with the greatest carcinogenic potential for the pleura [66]. Chrysotile (white asbestos), an easy-to-mould, heat-resistant, and non-acid-resistant asbestos, is known to be less toxic and accounts for 90% of asbestos used in the construction, textiles, and ceramics industry. Crocidolite (blue asbestos), resistant to acids, is the most toxic and hazardous variety, and, together with amosite, it has been the most widely used variety in the paper, board, and fibre cement industry [9, 60, 65, 67]. Only seven of the seventeen studies included presented the type of asbestos used, of which four were chrysotile, which is supported by the literature that states that chrysotile is the most common form used [68].

Inhalation is the most frequent and most damaging route to health [3, 9, 14, 67], which is supported by the seventeen studies included in this systematic review. In the included studies, according to the literature, the latency period has been established by taking into account the time that has elapsed from the first exposure to diagnosis [69], and mesothelioma occurs even at lower doses of asbestos exposure [4, 70].

The probability of developing MPM after exposure to asbestos depends on two factors: time since first exposure to asbestos and cumulative dose (fibres/mL of air x number of years of exposure) [71]. No formal studies were performed of the relationship between cumulative exposure and MPM after non-occupational exposures or investigated the risk associated with asbestos materials in place in living areas [72]. These data are supported by this systematic review since in seventeen studies, only one presents values related to cumulative exposure and in occupational context.

As regards the latency period, this systematic review found that the average latency period was approximately 42 years, with a minimum latency time of 1 year and a maximum of 91 years, with the first case identified in 1966 and the last in 2014. This is supported by the wider literature which demonstrates that although asbestos was banned in the European Union in 2005 [19], due to the long latency period (typically 20–50 years) [4, 7, 8, 14, 66, 71] between asbestos exposure and diagnosis of MPM, the incidence of MPM will continue to increase in Western Europe in the coming years [61], but it may be under-reported in many countries [54].

Although in this systematic review the mean age at first exposure was approximately 27 years, because of the long latency period of MPM, another reason for its incidence to be underestimated is that, since many individuals who were older at the time of exposure may not have had time to develop the disease [14], others may die prematurely from asbestosis or lung cancer or even from other diseases, such as cardiovascular diseases [14]. MPM has a very poor prognosis with a median survival from the diagnosis to death of approximately 9–12 months [73], which is supported for a number of studies included in this systematic review.

In regard to mortality from malignant pleural tumours, it was predicted that peak mortality would be reached in the early 2000 [13] as well as the incidence, considering the poor prognosis of this disease [12]. However, with the still current production and consumption [16, 17] and the unreported cases occurring in developing countries [55], problem that lobbyists against the ban

aim to keep [74], the global mesothelioma burden is unclear [75]. Deaths from mesothelioma are not clearly identified in the International Classification of Diseases (ICD) until the eighth revision, which took effect in 1968 [76]. A specific code for MPM has been available only since the tenth revision (ICD10), which was implemented since 1994, but continues not implemented in many countries [54], which supports the statement that mesothelioma deaths being reported worldwide do not reflect the historical asbestos usage in the world [77]. This systematic review reinforces the literature, as no study with the ICD10 code was identified, and only studies in which MPM was clinically and histologically validated could be included.

Another factor that might explain the fact that deaths from mesotheliomas are not clearly identified is that many studies related to mortality in MPM are based on post-mortem data, but the number of people who undergo an autopsy is not representative of the total number of people who die [14]. Due to the relatively scant information provided by the included studies, it is not possible to support these data since, although we know that in four studies they were identified in life, and in five post-mortem, in eight these data are unknown. Another aspect to be taken into consideration is the fact that industrializing countries, following the path of the industrialized countries, continue to produce and consume asbestos on a massive scale, countries that are major exporters of various products to industrialized countries, such as Mexico and China to the USA [78].

Surveillance programmes are recognized for providing an understanding of the health effects of exposure to asbestos [79] but also to improve clinical outcomes such as duration of survival and quality of life and to support research to advances in the detection, treatment, and prevention [80]. In that sense, a few countries, such as Italy and France in Europe, are among those that are most sensitive to the prevention and control of asbestos-related diseases, having a specific system of epidemiological surveillance of mesothelioma [5, 12, 81].

#### *Implications for Future Research*

The heterogeneity and relatively scant information of the data demonstrate that well-conducted cause-and-effect relationship between asbestos and MPM and exposure to asbestos history, incidence, and mortality to MPM assessment are required to improve the current evidence support.

#### *Limitations*

The main limitations of the conclusions of this review are the relatively scant information provided by the studies that could be obtained about asbestos exposure and incidence and mortality from MPM. The heterogeneity of the studies precluded meta-analysis. This review did not consider papers written in languages different from English, French, and Portuguese, and this might result in not considering relevant studies. Other aspects such as survival, diagnosis, treatment, and compensation were not considered in this review.

#### **Conclusions**

There is high evidence to support the relationship between asbestos and MPM, a disease of difficult diagnosis and poor prognosis. There is significant heterogeneity between the small number of identified studies as many are assessed as being of poor methodological quality and at a high risk of bias. All identified studies nevertheless support the relationship between asbestos and MPM, and reinforce the need for well-conducted research, and how research and surveillance are not inseparable. The implementation of National Mesothelioma Surveillance Centres at a global level is mandatory.

#### **Statement of Ethics**

Not required.

#### **Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

#### **Funding Sources**

This study received no funding.

#### **Author Contributions**

C.S., M.A.D., E.S.-L., P.A., and A.S.-U. conceived and designed the study. C.S. and M.A.D. screened the studies and extracted data. C.S. performed data analysis and wrote the first draft of this manuscript. All authors revised the manuscript and approved the final version. C.S. is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and no others meeting the criteria have been omitted.



## Data Availability Statement

The study protocol is available at [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42021242963](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021242963). Detailed extracted data on all included and excluded studies are available upon reasonable request to the corresponding author.

The guarantor of this review (C.S.) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Dissemination to participants and related patient and public communities: we plan to disseminate the findings and conclusions from this study through scientific conferences.

## References

- 1 Virta RL. *Asbestos: geology, mineralogy, mining, and uses*. New York, NY: U.S. Geological Survey. U.S. Department of the Interior; 2002.
- 2 Virta RL. *Worldwide asbestos supply and consumption trends from 1900 through 2003*. New York, NY: U.S. Geological Survey. U.S. Department of the Interior; 2006.
- 3 WHO.IARCWorld Health Organization. International Agency for Research on Cancer. *Agents classified by the IARC mMonographs: IARC monographs on the identification of carcinogenic hazards to humans: volumes 1–124*. Lyon: International Agency for Research on Cancer. World Health Organization; 2013 [cited 2021 Sep 25]. Available from: <https://monographs.iarc.fr/list-of-classifications>.
- 4 Markowitz S. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. *Semin Respir Crit Care Med*. 2015;36(03):334–46.
- 5 Chérié-Challine L, Gilg Soit Ilg A, Grange D, Bousquet PJ, Lafay L. *Dispositif national de surveillance des mésothéliomes intégrant la surveillance de leurs expositions: état des lieux des systèmes, enjeux de surveillance et recommandations*. Saint-Maurice: Santé Publique France; 2017.
- 6 Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut M, et al. The global burden of disease due to occupational carcinogens. *Am J Ind Med*. 2005;48(6):419–31.
- 7 Asbestos WHO. *World Health Organization. Asbestos: elimination of asbestos-related diseases*. Geneva: World Health Organization; 2017.
- 8 Chevalier A, Ducamp S, Gilg Soit Ilg A, Goldberg M, Goldberg S, Houot M, et al. *Indicators in occupational health: occupational risks due to asbestos*. Saint-Maurice: French Institute for Public Health Surveillance; 2011.
- 9 Mda Saúde . *Portugal. Ministério da Saúde. ACSS. Guia para procedimentos de inventariação de materiais com amianto e ações de controlo em unidades de saúde: G 03/2008*. Lisboa: Administração Central do Sistema de Saúde; 2011.
- 10 International Labour Organization. *World Health Organization Outline for the development of national programmes for elimination of asbestos-related diseases*. Paris: International Labour Organization; 2007.
- 11 Goldberg S, Rey G. *Modélisation de l'évolution de la mortalité par mésothéliome de la plèvre en France: projections à l'horizon 2050*. Saint-Maurice: Institut de Veille Sanitaire; 2012.
- 12 Gilg Soit Ilg A, Audignon S, Chamming's S, Ducamp S, Galateau-Sallé F, Gramond C, et al. *Programme National de Surveillance du Mésothéliome Pleural (PNSM): vingt années de surveillance (1998--2017) des cas de mésothéliome, de leurs expositions et des processus d'indemnisation*. Saint-Maurice: Santé Publique; 2019.
- 13 Lacourt A, Gramond C, Rolland P, Ducamp S, Audignon S, Astoul P, et al. Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma. *Thorax*. 2014;69(6):532–9.
- 14 Smith DD. *The health effects of asbestos: an evidence-based approach*. Boca Raton: Taylor & Francis; 2015.
- 15 Bianchi C, Bianchi T. Global mesothelioma epidemic: trend and features. *Indian J Occup Environ Med*. 2014;18(2):82–8.
- 16 International Asbestos Ban Secretariat. *Current asbestos bans*. 2021 [cited 2021 Dec 10]. Available from: [http://ibasecretariat.org/alpha\\_ban\\_list.php/](http://ibasecretariat.org/alpha_ban_list.php/).
- 17 U.S. Department of the interior U.S. Geological Survey. *National Minerals Information Center. Asbestos in 2020: tables-only release [Internet]*. New York, NY: U.S. Geological Survey; 2021 [cited 2022 Jan 20]. Available from: <https://www.usgs.gov/media/files/asbestos-2020-tables-only-release>.
- 18 Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Savès M, De Quillacq A, et al. The French National Mesothelioma Surveillance Program. *Occup Environ Med*. 2006;63(6):390–5.
- 19 World Health Organization. *The human and financial burden of asbestos in the WHO European Region*. Berlin: World Health Organization; 2013.
- 20 Fazzo L, Binazzi A, Ferrante D, Minelli G, Consonni D, Bauleo L, et al. Burden of mortality from asbestos-related diseases in Italy. *Int J Environ Res Public Health*. 2021;18(19):10012.
- 21 Ferrante P, Binazzi A, Branchi C, Marinaccio A. National epidemiological surveillance systems of mesothelioma cases. *Epidemiol Prev*. 2016;40(5):336–43.
- 22 Health and Safety, England Safety. *Mesothelioma statistics for Great Britain*. London: Health and Safety England; 2021.
- 23 Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality: United States, 1999–2015. *MMWR Morb Mortal Wkly Rep*. 2017;66(8):214–8.
- 24 López-Abente G, García-Gómez M, Menéndez-Navarro A, Fernández-Navarro P, Ramis R, García-Pérez J, et al. Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. *BMC Cancer*. 2013;13(1):528.
- 25 Gogou E, Kerenidi T, Chamos V, Zintzaras E, Gourgoulis KI. Mesothelioma mortality in Greece from 1983 to 2003. *Int J Clin Pract*. 2009;63(6):944–8.
- 26 Pedra F, Tambellini AT, Pereira Bde B, Carioca da Costa AC, Albuquerque de Castro HA. Mesothelioma mortality in Brazil, 1980–2003. *Int J Occup Environ Health*. 2008;14(3):170–5.
- 27 Fazzo L, Minelli G, De Santis M, Bruno C, Zona A, Conti S, et al. Epidemiological surveillance of mesothelioma mortality in Italy. *Cancer Epidemiol*. 2018;55:184–91.
- 28 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 29 Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfec R, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. *JBI manual for evidence synthesis*. Adelaide, AU: JBI; 2020.
- 30 Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. *Environ Health Perspect*. 2007;115(10):1401–5.
- 31 Goldberg M, Luce D. The health impact of nonoccupational exposure to asbestos: what do we know? *Eur J Cancer Prev*. 2009;18(6):489–503.
- 32 Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. *Br J Ind Med*. 1960;17(4):260–71.
- 33 Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. *CA Cancer J Clin*. 2019;69(5):402–29.



- 34 Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PCVJ, Vandenbroucke JP, et al. STROBE checklist: cohort, case-control, and cross-sectional studies (combined). *Lancet*. 2007;370(9596):1453–7.
- 35 Bianchi C, Bianchi T, Bucconi S. Malignant mesothelioma of the pleura in nonagenarian patients. *Tumori*. 2011;97(2):156–9.
- 36 Edge JR, Choudhury SL. Malignant mesothelioma of the pleura in Barrow-in-Furness. *Thorax*. 1978;33(1):26–30.
- 37 Acheson ED, Gardner MG, Bennett C, Winter PD. Mesothelioma in a factory using amosite and chrysotile asbestos. *Lancet*. 1981; 2318(8260–61):1403–6.
- 38 Cochrane JC, Webster I. Mesothelioma in relation to asbestos fibre exposure: a review of 70 serial cases. *S Afr Med J*. 1978;54(7):279–81.
- 39 Schneider J, Straif K, Weitowitz HJ. Pleural mesothelioma and household asbestos exposure. *Rev Environ Health*. 1996;11(1–2):65–70.
- 40 Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. *Lancet*. 1978;311(8073): 1061–3.
- 41 Méndez-Vargas MM, López-Rojas P, Campos-Pujal GA, Marín-Cotoñieto IA, Salinas-Tovar S, Fernández-Muñoz Mde DJ. Pleural mesothelioma in paraoccupational, environmental and occupational patients exposed to asbestos. *Rev Med Inst Mex Seguro Soc*. 2010; 48(4):361–6.
- 42 Merler E, Bizzotto R, Calisti R, Cavone D, De Marzo N, Gioffrè F, et al. Mesotheliomas among Italians, returned to the home country, who worked when migrant at a cement-asbestos factory in Switzerland. *SozPrventivmed*. 2003;48(1):65–9.
- 43 Orriols R, Tarrés J, Albertí-Casas C, Rosell-Murphy M, Abós-Herrándiz R, Canela-Soler J. Malignant asbestos-related disease in a population exposed to asbestos. *Am J Ind Med*. 2020;63(9):796–802.
- 44 Świątkowska B, Szeszenia-Dąbrowska N. Mesothelioma continues to increase even 40 years after exposure: evidence from long-term epidemiological observation. *Lung Cancer*. 2017;108:121–5.
- 45 D'Agostin F, de Michieli P, Negro C. Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy. *Int J Occup Med Environ Health*. 2017;30(3):419–31.
- 46 Finn RS, Brims FJH, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem findings of malignant pleural mesothelioma: a two center study of 318 patients. *Chest*. 2012;142(5):1267–73.
- 47 Berry G, Reid A, Aboagye-Sarfo P, de Klerk NH, Olsen NJ, Merler E. Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up. *Br J Cancer*. 2012;106(5):1016–20.
- 48 Mirabelli D, Calisti R, Fornero E, Merletti F, Magnani C. Excess of mesotheliomas after exposure to chrysotile in Balangero, Italy. *Occup Environ Med*. 2008;65:815–9.
- 49 Karjalainen A, Meurman LO, Pukkala E. Four cases of mesothelioma among Finnish anthophyllite miners. *Occup Environ Med*. 1994; 51(3):212–5.
- 50 Dodoli D, Del Nevo MD, Fiumalbi C, Iaia TE, Cristaudo A, Comba P, et al. Environmental household exposures to asbestos and occurrence of pleural mesothelioma. *Am J Ind Med*. 1992;21(5):681–7.
- 51 Milne J, Sc B. Fifteen cases of pleural mesothelioma associated with occupational exposure to asbestos in Victoria. *Med J Aust*. 1969; 2(14):669–73.
- 52 Kameda T, Takahashi K, Kim R, Jiang Y, Movahed M, Park E-K, et al. Asbestos: use, bans and disease burden in Europe. *Bull World Health Organ*. 2014;92(11):790–7.
- 53 Marsili D, Angelini A, Bruno C, Corfiati M, Marinaccio A, Silvestri S, et al. Asbestos ban in Italy: a major milestone, not the final cut. *Int J Environ Res Public Health*. 2017;14(11): e01379.
- 54 Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. *Annu Rev Public Health*. 2013;34(1):205–16.
- 55 Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. *Ann Cardiothorac Surg*. 2012;1(4):491–6.
- 56 OSH Wiki. *Asbestos [Internet]*. Bilbao: EU-OSHA; 2022 [cited 2021 Feb 20]. Available from: <https://oshwiki.eu/wiki/Asbestos>.
- 57 World Health Organization. *The 10 chemicals of major public health concern*. Geneva: World Health Organization; 2020. <https://www.who.int/teams/environment-climate-change-and-health/chemical-safety-and-health/health-impacts/chemicals/asbestos>.
- 58 Smolkova P, Nakladalova M, Zapletalova J, Jakubec P, Vildova H, Kolek V, et al. Validity of mesothelin in occupational medicine practice. *Int J Occup Med Environ Health*. 2016; 29(3):395–404.
- 59 Camiade E, Gramond C, Jutand MA, Audignon S, Rinaldo M, Imbernon E, et al. Characterization of a French series of female cases of mesothelioma. *Am J Ind Med*. 2013;56(11): 1307–16.
- 60 World Health Organization. *Chrysotile asbestos [Internet]*. Geneva: World Health Organization; 2014 [cited 2019 Sep 22]. Available from: <https://www.who.int/publications/i/item/9789241564816>.
- 61 Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma 2020. *Clin Transl Oncol*. 2021;23(5):980–7.
- 62 Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. *Br J Cancer*. 2009;100(7):1175–83.
- 63 Boulanger G, Andujar P, Pairon JC, Billon-Galland MA, Dion C, Dumortier P, et al. Quantification of short and long asbestos fibers to assess asbestos exposure: a review of fiber size toxicity. *Environ Health*. 2014;13: 59.
- 64 Lacourt A, Gramond C, Audignon S, Ducamp S, Févotte J, Soit Ilg AG, et al. Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica. *Am J Respir Crit Care Med*. 2013;187(9):977–82.
- 65 International Agency for Research on Cancer. *Working group on the evaluation of carcinogenic risks to humans. Asbestos: chrysotile, amosite, crocidolite, tremolite, actinolite, and anthophyllite*. Lyon: International Agency for Research on Cancer; 2011.
- 66 Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, De Vuyst P, et al. Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma. *Eur Respir J*. 2010;35(3):479–95.
- 67 Mateo M, Pérez-Carramiñana C, Chinchón S. El amianto en la edificación: variedades y riesgos asociados a las labores de deconstrucción. *Inf constr*. 2013;65(531):311–24.
- 68 Ogunseitan OA. The asbestos paradox: global gaps in the translational science of disease prevention. *Bull World Health Organ*. 2015; 93(5):359–60.
- 69 Pairon JC, Laurent F, Rinaldo M, Clin B, Andujar P, Ameille J, et al. Pleural plaques and the risk of pleural mesothelioma. *J Natl Cancer Inst*. 2013;105(4):293–301.
- 70 Sousa-Uva A. *Diagnóstico e Gestão do risco em saúde ocupacional*. 2a edição. Lisboa: ACT; 2010.
- 71 Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur Respir J*. 2020;55(6):1900953.
- 72 Ferrante D, Mirabelli D, Tunesi S, Terracini B, Magnani C. Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment. *Occup Environ Med*. 2016; 73(3):147–53.
- 73 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet*. 2005;366(9483): 397–408.
- 74 European Trade Union Institute for Research, Education and Health and Safety. *Asbestos in the world: special report: HESA Newsletter*. Brussels: ETUI-REHS; 2005.
- 75 Delgermaa V, Takahashi K, Park E-K, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the world health organization between 1994 and 2008. *Bull World Health Organ*. 2011;89(10):716–24.
- 76 Enterline PE, Henderson VL. Geographic patterns for pleural mesothelioma deaths in the United States, 1968–1981. *J Natl Cancer Inst*. 1987;79(1):31–7.

- 77 Courtice MN, Olsson AC, Cherrie JW. Less economically developed countries need help to create healthy workplaces. *Front Public Health*. 2019;7:257.
- 78 Frank AL. Global use of asbestos: legitimate and illegitimate issues. *J Occup Med Toxicol*. 2020;15:16.
- 79 Cavone D, Caputi A, De Maria L, Cannone ESS, Mansi F, Birtolo F, et al. Epidemiology of mesothelioma. *Environments*. 2019;6(7):76.
- 80 Cummings KJ, Becich MJ, Blackley DJ, Deapen D, Harrison R, Hassan R, et al. Workshop summary: potential usefulness and feasibility of a US National mesothelioma registry. *Am J Ind Med*. 2020;63(2):105–14.
- 81 Marinaccio A, Binazzi A, Marzio DD, Scarselli A, Verardo M, Mirabelli D, et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National register. *Int J Cancer*. 2012;130(9):2146–54.